查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1470939

疫苗佐劑市場：分產品、給藥途徑、疾病和應用 - 全球預測 2024-2030

Vaccine Adjuvants Market by Product (Adjuvant Emulsions, Combination Adjuvants, Mineral Adjuvants), Route of Administration (Intradermal, Intramuscular, Intranasal), Disease, Application - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2023年疫苗佐劑市場規模為8.2565億美元，預計2024年將達8.8418億美元，2030年將達到14.042億美元，複合年成長率為7.88%。

疫苗佐劑是疫苗製劑的重要組成部分，可增強和調節疫苗中所含抗原引發的免疫反應。疫苗佐劑包括鋁鹽、油乳劑、皂素、細胞激素、 類鐸受體致效劑等多種產品。疫苗佐劑有多種應用，包括感染疾病、癌症免疫治療、過敏治療、自體免疫疾病管理和獸醫學。開拓市場成長要素包括由於公眾對預防醫學的認知不斷提高而導致對有效疫苗的需求增加、政府和私人公司對研發活動的投資增加以及新興市場的有利報銷政策。此外，新的疫苗接種技術，例如基於 mRNA 的方法，預計將推動對有效佐劑的需求。與學術機構和小型生物技術公司合作進行新型佐劑研究，推出針對特定免疫機制的創新佐劑來解決未滿足的臨床需求，將為疫苗佐劑市場帶來巨大的前景。然而，市場面臨嚴格的監管流程、高昂的開發和製造成本、與某些助劑相關的潛在安全問題以及導致競爭加劇和報酬率下降的專利到期等限制。最佳化佐劑功效和安全性組合的挑戰可能會抑制採用率。

主要市場統計
基準年[2023] 8.2565億美元
預測年份 [2024] 88418萬美元
預測年份 [2030] 1,404.2 百萬美元
複合年成長率（%） 7.88%

疫苗佐劑的使用激增以提高癌症疫苗的功效

在腫瘤學中，疫苗佐劑旨在增強針對腫瘤抗原的免疫反應，提高癌症疫苗的功效，而癌症相關佐劑與腫瘤抗原結合，特異性激發抗腫瘤免疫。疫苗佐劑用於感染疾病，以增強疫苗對病毒、細菌和寄生蟲的效力。感染疾病的疫苗佐劑主要著重於預防而非治療。這些佐劑刺激更廣泛的免疫反應，包括體液和細胞介導的免疫。此外，這些佐劑已在大規模免疫宣傳活動中進行了廣泛測試，並表現出既定的安全性。

產品 免疫系統受損的患者越來越青睞佐劑乳劑

佐劑乳液是油和水的混合物，充當抗原的疫苗載體。佐劑乳劑透過更好地將抗原遞送至免疫細胞來增強免疫反應。乳液因其穩定性、多功能性和易於製造而受到優選。合併佐劑是使用兩種或兩種以上不同類型的佐劑，利用協同效應來提高疫苗製劑中抗原的整體免疫抗原性。當單組分佐劑單獨無法提供最佳免疫反應時，通常會採用此方法。礦物質佐劑基於鋁鹽和磷酸鈣等化合物，它們充當儲庫形成劑，增強呈現抗原並延長免疫反應。顆粒佐劑由奈米顆粒或微粒組成，可以有效地遞送抗原，透過模仿病原體的結構來刺激先天性和適應性免疫。這些佐劑通常用於針對特定病原體或癌細胞。

人類用疫苗中疫苗佐劑的使用增加

人類佐劑包括有效且安全的標靶疫苗，用於對抗感染疾病、癌症和其他健康狀況。佐劑在人類疫苗中的使用已顯著擴大，因為它們能夠增強免疫反應，從而節省劑量並減少所需抗原的量，從而實現具有成本效益的疫苗生產。佐劑在獸用疫苗中發揮重要作用，可預防和控制動物感染疾病，確保食品安全、公共衛生和動物整體福祉。獸用佐劑的偏好是基於功效、安全性、免疫抗原性、與抗原的生物相容性、易用性和穩定性。

給藥途徑：透過皮內給藥擴大疫苗佐劑的使用

皮內注射涉及將疫苗佐劑直接注射到皮膚中，從而產生有針對性的局部免疫反應。這種方法對於需要細胞介導的固態免疫的疫苗特別有效，例如卡介苗（BCG）和某些流感疫苗。肌肉注射是刺激強大的全身免疫反應的有效方法，適用於大多數疫苗，包括B型肝炎和人類乳突病毒 (HPV)。鼻內給藥透過鼻黏膜輸送疫苗佐劑，促進局部黏膜免疫反應，以防止空氣傳播的病原體。口服疫苗佐劑透過攝取或舌下吸收誘導全身和黏膜免疫。此途徑適用於輪狀病毒等腸道病原體，具有給藥方便、提高病患依從性的優點。皮下注射將疫苗沉積在皮下，以延長抗原暴露時間並增強免疫反應，當肌肉注射有風險或需要緩釋性機制時使用。

區域洞察

美洲的疫苗佐劑市場正在發展，對增強免疫反應的創新佐劑的需求很高。美國政府正大力投資研究舉措，以支持佐劑的開發。歐盟 (EU) 由於其成熟的醫療基礎設施和正在進行的臨床試驗，顯示出疫苗佐劑的巨大成長潛力。在中東，一些國家正在政府和非政府組織的支持下積極加強免疫計畫。非洲地區疫苗佐劑的成長得益於國際組織、政府和非政府組織對免疫計畫的資助增加。由於對先進疫苗技術的投資，亞太地區的疫苗佐劑市場正在成長。鑑於開發新型疫苗技術的重點，疫苗佐劑的使用預計也將在全球最終用途領域擴大。

FPNV定位矩陣

FPNV定位矩陣對於評估疫苗佐劑市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出明智的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可以對疫苗佐劑市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴見解，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更明智的決策並制定有效的策略，從而在市場上獲得競爭優勢。

本報告在以下方面提供了寶貴的見解：

1. 市場滲透率：提供有關主要企業所服務的市場的全面資訊。

2. 市場開拓：我們深入研究利潤豐厚的新興市場，並分析其在成熟細分市場的滲透率。

3. 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。

4.競爭評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。

5. 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。

本報告解決了以下關鍵問題：

1.疫苗佐劑市場規模及預測如何？

2.疫苗佐劑市場預測期間需要考慮投資的產品、區隔市場、應用和領域有哪些？

3.疫苗佐劑市場的技術趨勢和法規結構是什麼？

4.疫苗佐劑市場主要廠商的市場佔有率是多少？

5.進入疫苗佐劑市場的合適業態和策略手段是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 感染疾病和通用感染疾病的發生率增加
      • 需要提高疫苗的有效性
      • 畜牧業的擴張和相關疾病的傳播
    • 抑制因素
      • 礦物佐劑與重組蛋白及次單位疫苗的不相容性
    • 機會
      • 複合佐劑的潛力不斷成長
      • 擴大疫苗開發
    • 任務
      • 資本集中且耗時的開發與核准流程
  • 市場區隔分析
    • 疾病：使用疫苗佐劑提高癌症疫苗效力激增
    • 產品：佐劑乳劑在免疫力較弱的人中越來越受歡迎。
    • 應用：增加人類疫苗中疫苗佐劑的使用
    • 給藥途徑：透過皮內給藥增加疫苗佐劑的使用
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第6章疫苗佐劑市場：依產品

  • 佐劑乳劑
  • 複方佐劑
  • 礦物佐劑
  • 顆粒佐劑

第7章疫苗佐劑市場：途徑

  • 皮內
  • 肌肉注射
  • 鼻內
  • 口服
  • 皮下的

第8章疫苗佐劑市場：依疾病分類

  • 癌症
  • 感染疾病

第9章疫苗佐劑市場：依應用分類

  • 人類
  • 動物

第10章 美洲疫苗佐劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太疫苗佐劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲疫苗佐劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 普利茲克分子工程學院與工業界合作開發下一代疫苗
    • Croda Partners 疫苗佐劑
    • 牛津大學開發的 R21/Matrix M 瘧疾疫苗獲准在加納使用
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-02026C4C8667

[183 Pages Report] The Vaccine Adjuvants Market size was estimated at USD 825.65 million in 2023 and expected to reach USD 884.18 million in 2024, at a CAGR 7.88% to reach USD 1,404.20 million by 2030.

Vaccine adjuvants are essential components in the formulation of vaccines, which enhance and modulate the immune response elicited by the antigen present in the vaccine. The vaccine adjuvants encompass various products, including aluminum salts, oil emulsions, saponins, cytokines, and toll-like receptor agonists. The vaccine adjuvants have diverse applications, such as infectious diseases, cancer immunotherapy, allergy treatment, autoimmune disorders management, and veterinary medicine. Growth factors driving the market include growing demand for effective vaccines due to heightened public awareness about preventive healthcare measures, rising investments from governments and private entities for research & development activities, and favorable reimbursement policies in developed markets. Additionally, novel vaccination technologies such as mRNA-based approaches are anticipated to boost demand for effective adjuvants. Partnering with academic institutes or smaller biotechnology companies for novel adjuvant research and introduction of innovative adjuvants targeting specific immune mechanisms and addressing unmet clinical needs offers substantial prospects for the vaccine adjuvant market. However, the market faces limitations such as stringent regulatory processes, high development & manufacturing costs, potential safety concerns associated with specific adjuvants, and patent expirations leading to increased competition and reduced profit margins. The challenges in optimizing adjuvant combinations for efficacy and safety may impede adoption rates.

KEY MARKET STATISTICS
Base Year [2023] USD 825.65 million
Estimated Year [2024] USD 884.18 million
Forecast Year [2030] USD 1,404.20 million
CAGR (%) 7.88%

Diseases: Burgeoning use of vaccine adjuvants to increase the efficacy of cancer vaccines

In oncology, vaccine adjuvants enhance the immune response against tumor antigens, aiming to increase the efficacy of cancer vaccines, and cancer-related adjuvants are combined with tumor antigens to stimulate anti-tumor immunity specifically. Vaccine adjuvants have been utilized in infectious diseases to boost vaccine efficacy against viruses, bacteria, and parasites. Infectious disease vaccine adjuvants primarily focused on prevention rather than therapy. These adjuvants stimulate a broader immune response, including humoral and cellular immunity. Additionally, these adjuvants have been extensively tested in mass vaccination campaigns and exhibit an established safety profile.

Product: Increasing preference for adjuvant emulsions for those with compromised immune systems

Adjuvant emulsions are mixtures of oil and water that serve as a vaccine carrier for antigens. These emulsions enhance the immune response by delivering better antigens to immune cells. They are preferred due to their stability, versatility, and ease of production. Combination adjuvants use two or more different types of adjuvants to leverage synergistic effects for enhancing the overall immunogenicity of antigens within a vaccine formulation. This approach is usually employed when single-component adjuvants may not provide optimal immune responses alone. Mineral adjuvants are based on compounds like aluminum salts or calcium phosphate, which serve as depot-forming agents to enhance antigen presentation and prolong the immune response. Particulate adjuvants consist of nano or microparticles that can effectively deliver antigens and stimulate innate and adaptive immunity by mimicking the pathogen's structure. These adjuvants are usually employed when targeting specific pathogens or cancer cells.

Application: Increasing use of vaccine adjuvants for human vaccines

The human adjuvant has effective, safe, and targeted vaccines to combat infectious diseases, cancer, and other health conditions. The application of adjuvants in human vaccines has grown significantly due to their ability to enhance immune responses, allowing dose sparing and reducing the amount of antigen needed, which leads to cost-effective vaccine production. Adjuvants play a crucial role in veterinary vaccines to prevent and control infectious disorders in animals, ensuring food safety, public health, and overall animal welfare. Preferences for veterinary adjuvants are based on efficacy, safety, immunogenicity, biocompatibility with antigens, ease of use, and stability.

Route of Administration: Proliferating use of vaccine adjuvants through intradermal administration

Intradermal administration involves the injection of the vaccine adjuvant directly into the skin, allowing for a targeted and localized immune response. This method is particularly effective for vaccines that require cell-mediated solid immunity, such as Bacille Calmette-Guerin (BCG) and certain influenza vaccines. The intramuscular route provides an efficient means to stimulate a robust systemic immune response suitable for most vaccines, including Hepatitis B and human papillomavirus (HPV). Intranasal administration involves delivering the vaccine adjuvant through the nasal mucosa, promoting a local mucosal immune response to protect against airborne pathogens - ideal for respiratory infections such as influenza. Oral administration of vaccine adjuvants employs ingestion or sublingual absorption to induce systemic and mucosal immunity. This route is preferred for enteric pathogens, such as rotavirus, and offers advantages, providing ease of administration and improved patient compliance. Subcutaneous injections deposit the vaccine beneath the skin for prolonged antigen exposure and enhanced immune response, used when intramuscular injection might pose risks or require slow-release mechanisms.

Regional Insights

The vaccine adjuvants market is evolving in the Americas with a high demand for innovative adjuvants to enhance immune responses. The U.S. government is investing heavily in research initiatives to support adjuvant discovery. The European Union represents substantial growth potential for vaccine adjuvants due to its well-established healthcare infrastructure and ongoing clinical trials. In the Middle East, several nations are actively boosting their immunization programs with assistance from government and non-governmental organizations. The African region's growth in vaccine adjuvants can be attributed to increased funding for immunization programs by international organizations, governments, and NGOs. The vaccine adjuvants market is growing in the APAC region owing to investments in advanced vaccine technologies. Besides, emphasis on the development of novel vaccine technologies is anticipated to boot the use of vaccine adjuvants across the end-use sectors globally.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Vaccine Adjuvants Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Vaccine Adjuvants Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Vaccine Adjuvants Market, highlighting leading vendors and their innovative profiles. These include Agenus Inc., Aphios Corporation, Bioveta, A.S., Croda International PLC, CSL Limited, Dynavax Technologies Corporation, GlaxoSmithKline PLC, Hayashibara Co., Ltd. by NAGASE & CO., LTD., InvivoGen, Merck KGaA, Novavax, Inc., OZ Biosciences SAS, Pacific GeneTech Limited, Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Vaccine Adjuvants Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Adjuvant Emulsions
    • Combination Adjuvants
    • Mineral Adjuvants
    • Particulate Adjuvants
  • Route of Administration
    • Intradermal
    • Intramuscular
    • Intranasal
    • Oral
    • Subcutaneous
  • Disease
    • Cancer
    • Infectious Diseases
  • Application
    • Human
    • Veterinary
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Vaccine Adjuvants Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Vaccine Adjuvants Market?

3. What are the technology trends and regulatory frameworks in the Vaccine Adjuvants Market?

4. What is the market share of the leading vendors in the Vaccine Adjuvants Market?

5. Which modes and strategic moves are suitable for entering the Vaccine Adjuvants Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing incidences of infectious and zoonotic diseases
      • 5.1.1.2. Need to increase the effectiveness of vaccines
      • 5.1.1.3. Growth in livestock operations and prevalence of associated diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Incompatibility of mineral adjuvant with recombinant proteins and sub-unit vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Rising potential of combination adjuvants
      • 5.1.3.2. Increasing development of vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Capital-intensive and time-consuming development and approval process
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Diseases: Burgeoning use of vaccine adjuvants to increase the efficacy of cancer vaccines
    • 5.2.2. Product: Increasing preference for adjuvant emulsions for those with compromised immune systems
    • 5.2.3. Application: Increasing use of vaccine adjuvants for human vaccines
    • 5.2.4. Route of Administration: Proliferating use of vaccine adjuvants through intradermal administration
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Vaccine Adjuvants Market, by Product

  • 6.1. Introduction
  • 6.2. Adjuvant Emulsions
  • 6.3. Combination Adjuvants
  • 6.4. Mineral Adjuvants
  • 6.5. Particulate Adjuvants

7. Vaccine Adjuvants Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Intradermal
  • 7.3. Intramuscular
  • 7.4. Intranasal
  • 7.5. Oral
  • 7.6. Subcutaneous

8. Vaccine Adjuvants Market, by Disease

  • 8.1. Introduction
  • 8.2. Cancer
  • 8.3. Infectious Diseases

9. Vaccine Adjuvants Market, by Application

  • 9.1. Introduction
  • 9.2. Human
  • 9.3. Veterinary

10. Americas Vaccine Adjuvants Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Vaccine Adjuvants Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Vaccine Adjuvants Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Pritzker School of Molecular Engineering enters Academic-Industry partnership to create Next Generation vaccines
    • 13.3.2. Croda Partners on Vaccine Adjuvants
    • 13.3.3. R21/Matrix-M Malaria Vaccine Developed By University Of Oxford Receives Regulatory Clearance For Use In Ghana
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. VACCINE ADJUVANTS MARKET RESEARCH PROCESS
  • FIGURE 2. VACCINE ADJUVANTS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. VACCINE ADJUVANTS MARKET DYNAMICS
  • FIGURE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. VACCINE ADJUVANTS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. VACCINE ADJUVANTS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. VACCINE ADJUVANTS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL VACCINE ADJUVANTS MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ADJUVANT EMULSIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ADJUVANT EMULSIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COMBINATION ADJUVANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY COMBINATION ADJUVANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MINERAL ADJUVANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY MINERAL ADJUVANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATE ADJUVANTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY PARTICULATE ADJUVANTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRADERMAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRADERMAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INTRANASAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY ORAL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HUMAN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY HUMAN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VETERINARY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL VACCINE ADJUVANTS MARKET SIZE, BY VETERINARY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES VACCINE ADJUVANTS MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA VACCINE ADJUVANTS MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY DISEASE, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND VACCINE ADJUVANTS MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 353. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 354. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 355. TURKEY VACCINE ADJUVANTS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2023 (USD MILLION)
  • TABLE 356. TURKEY VACCINE ADJ